R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
PP&E Gross
ÂĄ40.9m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
PP&E Gross
ÂĄ26.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
PP&E Gross
ÂĄ10.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
PP&E Gross
ÂĄ1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
PP&E Gross
ÂĄ1.2B
CAGR 3-Years
60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's PP&E Gross?
PP&E Gross
40.9m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's PP&E Gross amounts to 40.9m CNY.

What is R&G PharmaStudies Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 3Y
18%

Over the last year, the PP&E Gross growth was -22%. The average annual PP&E Gross growth rates for R&G PharmaStudies Co Ltd have been 18% over the past three years .

Back to Top